EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma

Julian Kött, Glenn Geidel iD, Carmen M T Roeper, Lucija Ačkar, Bente Siebels, Hannah Voß, Hartmut Schlüter, Michaela Schweizer, Kilian Müller, Alessandra Rünger, Tim Zell iD, Benjamin Deitert und 6 weitere

International Journal of Cancer · 01.12.2026 · 159 (11) · 2824-2834

DOI: 10.1002/ijc.70650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 12.07.2026. Verfasst von Julian Kött und 17 weiteren Autor:innen. Beteiligte Einrichtung: Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Melanoma, Extracellular Vesicles, Drug Resistance, Neoplasm, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Hiege-Stiftung - die Deutsche Hautkrebsstiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking. As key mediators of cellular communication, extracellular vesicles (EVs) represent promising biomarkers. This study aimed to identify baseline EV proteome–derived pathways and biomarkers associated with overall, primary, and secondary resistance to ICI in advanced melanoma and to derive biomarker signatures predictive of progression‐free survival (PFS). EVs were isolated from pretreatment plasma samples of 46 patients with advanced melanoma using size exclusion chromatography and ultracentrifugation. Proteomic profiling was performed by liquid chromatography–mass spectrometry using DIA‐NN. Pathway enrichment and network analyses were conducted using Reactome, Metascape, Cytoscape, and DAVID. Resistance‐associated proteins were integrated into composite biomarker signatures and evaluated for association with PFS. Overall resistance was characterized by enrichment of platelet‐ and complement‐associated pathways. Primary resistance was associated with enhanced Fc gamma receptor (FCGR) signaling and downregulation of KSRP‐associated post‐transcriptional regulatory processes. In contrast, secondary resistance was preceded by distinct baseline EV proteomic patterns involving complement activation and reduced hemostasis‐ and platelet‐related pathways. EV‐derived biomarker signatures for overall, primary, and secondary resistance independently discriminated patients according to PFS. Baseline plasma EV proteomics reveals distinct systemic biological programs associated with different resistance phenotypes to ICI in advanced melanoma. EV‐derived biomarker signatures enable stratification by PFS and warrant validation in larger, multicentric cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaExtracellular VesiclesDrug Resistance, NeoplasmProteomeBiomarkers, TumorHumansFemaleMaleImmunotherapyProteomicsMiddle AgedImmune Checkpoint InhibitorsAged

Stichwörter der Autor:innen

biomarkerextracellular vesiclesimmune checkpoint inhibitorimmunotherapymass spectrometrymelanomaprimary resistanceproteomicssecondary resistance

Substanzen

ProteomeBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Section Mass Spectrometry and Proteomics, Center of Diagnostics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Glenn Geidel, Tim Zell, Daniel J Smit

Förderung

  • Deutsche Forschungsgemeinschaft
  • Hiege-Stiftung - die Deutsche Hautkrebsstiftung

Zitieren

APA

Kött, J., Geidel, G., Roeper, C. M. T., Ačkar, L., Siebels, B., Voß, H., Schlüter, H., Schweizer, M., Müller, K., Rünger, A., Zell, T., Deitert, B., Zeinal-Abedini, A., Heidrich, I., Schneider, S. W., Pantel, K., Smit, D. J., & Gebhardt, C. (2026). Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma. International Journal of Cancer, 159(11), 2824-2834. https://doi.org/10.1002/ijc.70650

Vancouver

Kött J, Geidel G, Roeper CMT, Ačkar L, Siebels B, Voß H, et al. Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma. International Journal of Cancer. 2026;159(11):2824-2834. doi:10.1002/ijc.70650

BibTeX
@article{Ktt2026,
  author = {Kött, Julian and Geidel, Glenn and Roeper, Carmen M T and Ačkar, Lucija and Siebels, Bente and Voß, Hannah and Schlüter, Hartmut and Schweizer, Michaela and Müller, Kilian and Rünger, Alessandra and Zell, Tim and Deitert, Benjamin and Zeinal-Abedini, Ali and Heidrich, Isabel and Schneider, Stefan W and Pantel, Klaus and Smit, Daniel J and Gebhardt, Christoffer},
  title = {Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {11},
  pages = {2824--2834},
  doi = {10.1002/ijc.70650}
}
Kostenlos starten →